Purpose To test the psychometric properties of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Rasch-based methods. Methods A secondary data analysis was performed using pooled QLQ-CIPN20 data from patients (N = 1008) who had participated in any of four multi-site chemotherapy-induced peripheral neuropathy (CIPN) treatment and prevention trials. QLQ-CIPN20 responses were evaluated using a polytomous Rasch partial credit model. Data were assessed for person-item fit using the chi-square statistic, item scaling based on response proportions, threshold ordering using item characteristic curves and logit threshold locations, differential item response (DIF) (i.e., response bias) using likelihood ratio tests, and unidimensionality using cluster analysis. Results A statistically significant chi-square test indicated poor fit of the observed to the expected responses. More than 70% of the respondents reported a complete absence of six symptoms, reflecting significant floor effects and poor item scaling. Disordered/non-ordinal or narrow response thresholds were found for 11 of the 20 items. Item responses were significantly different by gender (p < 0.0001) and chemotherapy type (p < 0.0001). Cluster analysis findings suggest that the QLQ-CIPN20 is a unidimensional scale due to the absence of item clusters. Conclusions Rasch model testing revealed psychometric weaknesses that could be addressed by revising the QLQ-CIPN20's problematic items and response options. Alternatively, perhaps the new gold standard CIPN measurement approach in future intervention trials should involve use of only the best items, which would also allow comparisons across previous trials that utilized the QLQ-CIPN20.
Introduction
Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting toxicity associated with a number of commonly used antineoplastic therapies [1] . CIPN symptoms-typically tingling, numbness, pain, weakness, and a loss of reflexes in the extremities-can affect as many as 60% of patients receiving neurotoxic cancer therapy by their third month of treatment [2] . In addition to being distressing, symptoms can become debilitating, forcing providers to alter or stop cancer therapy [3] . Studies also show that CIPN is associated with falls [4, 5] , disturbed sleep [6, 7] , difficulty performing workrelated tasks [8] , increased healthcare utilization [9] , and greater use of medication (including opioids) to manage symptoms [9, 10] . Methods for preventing CIPN have yet to be identified [1] , increasing the need for trials evaluating potential interventions.
Currently, several measures, but no gold-standard approach, are used to evaluate CIPN in intervention trials [11, 12] , including grading scales such as the National Cancer Institute Common Toxicity Criteria Adverse Events (CTCAE) [11] , and the different versions of the Total Neuropathy Score (TNS), which combine questions about CIPN symptoms with simplified physical assessment procedures [13, 14] . Several patient-reported outcome (PRO) measures that evaluate patients' perceptions of their CIPN have also been developed [15] . Examples of CIPN PRO measures include the Patient Neurotoxicity Questionnaire (PNQ) [16] , the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT-GOG/Ntx) scale [17, 18] , and the European Organisation for Research and Tr ea tme nt of C an ce r (EORT C) Qua lit y o f Li fe Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) [19] . Because the QLQ-CIPN20 has been widely used and extensively tested [20] [21] [22] [23] [24] [25] [26] [27] [28] , it has potential to move forward as the gold standard PRO measure.
An important issue in how PRO measures like the QLQ-CIPN20 have been tested is our reliance on classical test theory (CTT). CTT assumes that the distance between items on a scale, like inches on a ruler, is equal [29, 30] . While CTT-based procedures are well-suited for validating measures with interval or ratio-level items, CTT is poorly suited for testing the QLQ-CIPN20's ordinal-level item responses (i.e., 1 = not at all, 2 = a little bit, 3 = quite a bit, 4 = very much). Since the distance between its response levels cannot be assumed to be equal, this can lead to floor and ceiling effects that undermine sensitivity. Another assumption of CTT is that when items are summed to create a total score, all items have equal importance/weight [29] and, therefore, can be combined into different subscales. In the case of the QLQ-CIPN20, items have been summed to obtain three subscale scores (sensory, motor, and autonomic). However, neither this subscale structure nor the relative weight of the items has yet been established empirically; further, recent evidence suggests that the QLQ-CIPN20 may perform better as a unidimensional scale [23, 25] .
One way to overcome the limitations associated with CTTbased methods for testing ordinal-level measures like the QLQ-CIPN20 is to use models based on Item Response Theory (IRT) instead. Unlike CTT-models, IRT-models use probability to determine the likelihood that patients with symptoms at a certain level of severity (e.g., moderately severe CIPN) will select a given response on a corresponding scale (e.g., 2 = moderate symptoms) [31] . The Rasch model, a specific type of IRT model, is based on the assumption that a scale is unidimensional (i.e., items do not cluster into subscales), and compares individual item response patterns from the entire sample to the person location estimates (symptom severity) and item difficulty (based on the proportion of patients who select a particular response option) [31] . Person estimates (severity) and item response patterns (difficulty) are then reflected in a logit-based interval scale [31] . Like other IRT models, Rasch models assume that patients with more severe symptoms will have a higher probability of selecting responses that reflect worse symptom severity [31] . This relationship between symptom severity and the probability that participants will select a specific response can be illustrated using an item characteristic curve ( Fig. 1) [29, 31] . When using QLQ-CIPN20 items to measure CIPN severity, each curve in Fig. 1 represents the probability (y-axis) that the patient will rate CIPN items as 1 (black curve = not at all), 2 (green curve = a little), 3 (red curve = quite a bit), or 4 (purple curve = very much) based on their CIPN severity. The x-axis (estimate person location logits) reflects low to high CIPN severity-the latent trait. Points where the curves overlap indicate equal probability of selecting either response. These overlapping points, the logit threshold, can be used to determine if the data are consistent with an ordinal level of measurement. Logit threshold location values should be ordered from low to increasingly higher values. When the data are not ordered, this suggests that respondents are unable to distinguish the difference between the first-and second-highest response options and, perhaps, a more granular response criterion (e.g., 0-10) would facilitate better distinction between subtle differences.
Rasch models have several advantages for evaluating CIPN PRO measures over CTT-based techniques. First, provided that a test's assumptions are met, Rasch techniques have the ability to convert ordinal responses to more precise interval-level responses [31] , making it possible to use statistical techniques generally reserved for interval-level data [32] . Second, Rasch models can be used to identify redundant items and restrictive item-response criteria that can negatively compromise the sensitivity and validity of the measures. Rasch techniques can also be used to evaluate item bias (differential item functioning [DIF] ): variations in responses based on a participant's unique characteristics such as age, gender, diagnosis, or cultural background [31] . Minimizing item bias is particularly important for CIPN PRO measures so that these tools will provide valid and reliable data on CIPN severity in diverse populations [30] .
Therefore, the purpose of this secondary data analysis was to perform additional testing on the EORTC QLQ-CIPN20 using Rasch analysis. The goal was to gain additional insight regarding the CIPN20's psychometric properties in an effort to improve its ability to detect and quantify CIPN in individuals with diverse demographic characteristics.
Methods
Sample QLQ-CIPN20 data were obtained from a large pooled sample (N = 1008) of patients who had participated in any of four multi-site CIPN treatment and prevention trials (N06CA, N08C1, N08CA, and N08CB) conducted by the North Central Cancer Treatment Group (NCCTG) [10, [33] [34] [35] , which is now part of the Alliance for Clinical Trials in Oncology, a large National Cancer Institute (NCI)-funded multisite cancer research network. Institutional review boards at participating sites approved all of the original studies, and written informed consent was obtained from all participants.
One randomized double-blind, placebo-controlled trial (RCT) (N06CA) tested the efficacy for CIPN of a topical compounded cream containing baclofen, amitriptyline, and ketamine (BAK) in patients with CIPN due to a variety of neurotoxic chemotherapy drugs [35] . In N08C1, the QLQ-CIPN20 was used to describe CIPN patterns over time in patients who had received paclitaxel [10, 33] . Two of the four studies were RCTs designed to test drugs to prevent CIPN caused by paclitaxel/carboplatin (N08CA) [36] and oxaliplatin (N08CB) [34] . The eligibility criteria for these four studies have been previously described [10, [33] [34] [35] [36] . Of note, two of the intervention studies were negative, and one (N06CA) showed a trend favoring topical BAK cream for sensory neuropathy and statistically significant improvements in motor neuropathy.
The QLQ-CIPN20
The QLQ-CIPN-20 [19] is a 20-item self-report questionnaire originally designed to supplement the EORTC Quality of Life Questionnaire. Based on the initially hypothesized factor structure, it contains 9 items assessing sensory neuropathy, 8 assessing motor function, and 3 assessing autonomic neuropathy (i.e., dizziness, erectile dysfunction, and blurred vision). Items are scored 1-4 with 1 representing Bnot at all^and 4 Bvery much.^Item scores are summed to obtain subscale scores. However, recent evidence suggests that all items can be summed to obtain a total CIPN score [23] . Scores are then linearly converted to a 0-100 scale [37] .
Statistical analyses
Descriptive statistics (i.e., mean, standard deviation [SD], range, and frequency) were calculated for demographics (i.e., age and gender), chemotherapy variables (i.e., parent protocol, chemotherapy treatment [if known]), and QLQ-CIPN20 scores. The QLQ-CIPN20 data used in the analyses reflect the point of greatest CIPN severity for the patients in each study.
The QLQ-CIPN20 responses were evaluated using a polytomous Rasch model using eRm package [38] because the item responses ranged from 1 = not at all to 4 = very much. The partial credit model (PCM) was used because the distances between overlapping points on the response curves varied across the items. Chi-square statistics were used to assess the difference between the observed and expected responses across individual item responses. A nonsignificant chi-square indicates a good fit [31] . To determine whether the items were appropriately targeted (item targeting) to encompass the full range of CIPN severity, a zero logit was selected to represent average severity, with a negative logit value indicating mild or below average neuropathy and a positive logit indicating above average/more severe CIPN [31] . This approach is used to determine the presence of floor or ceiling effects based on the proportion of low-high logit values.
Threshold ordering was evaluated using item characteristic curves and logit threshold locations, which indicate whether item scores reflect an ordered/ordinal response [31] . The point where two adjacent response category curves intersect (logit threshold locations), which indicates that either response is equally probable, was assessed to determine if patients were able to distinguish between the various response options.
Differential item functioning (DIF) was assessed as a measure of item bias using the likelihood ratio test. DIF testing indicates whether item responses differ within sample subgroups (e.g., male/female, neuropathy subtypes) [39] . Although age is another demographic variable commonly used to assess DIF, age was not used as a DIF variable in this study: because peripheral nerve function normally deteriorates with age, differing item responses between younger and older participants would be expected and not indicative of item bias [27] .
K-means clustering method was used to explore various empirical partitions of the observed data. Since the Rasch model is based on the assumption that the summed item score reflects a unidimensional construct, items should not form significant clusters [31] .
Results

Demographics
The demographic characteristics of the pooled sample (N = 1008) are reported in Table 1 . Age, gender, and chemotherapy type were the demographic variables common to all four Alliance studies. Participants' mean age was 58.8 years (SD = 11.2; range 23.0-89.0) and most were female (68.8%). Most participants received oxaliplatin (34.7%), 31.5% received paclitaxel plus carboplatin, and 13.5% received paclitaxel alone; the remaining 20.2% (BAK participants) received various neurotoxic drugs/combinations. The sample included patients with myeloma, lymphoma, and colon, breast, lung, and ovarian cancer; however, frequency data are not available for every study. Similarly, race frequencies are available for only 10% of the sample, and thus are not reported.
Item and person fit
The chi-square test tests the assumption that the probability of selecting a specific item response (e.g., 1 = not at all) will be closely aligned with symptom severity. A statistically significant chi-square test for four items (#16, 17, 18, and 20) (p < 0.0001) indicated that item responses for questions assessing dizziness, blurred version, hearing, and erectile dysfunction were not aligned with symptom severity.
Scale targeting
Tingling and numbness in the fingers or hands (mean = 2.3, 2.2; SD = 1.0) and toes or feet (mean = 2.3, SD = 1.1) were the most severe symptoms. Difficulty using pedals was reported infrequently, with just 11.5% of participants reporting a mean score of greater than 1.1 (SD = 0.4). All items encompassed the entire score range (1) (2) (3) (4) . Response distributions are also illustrated in Fig. 2 . The high proportion of low severity responses suggests that the 1-4 response range does not adequately capture subtle nuances in symptom severity. Specifically, a high proportion (> 70%) of patients denied having burning pain in fingers or hands (item #5), hand cramps (item #7), difficulty distinguishing between hot and cold water (item #10), difficulty walking due to foot drop (item #14), hearing loss (item #18), or difficulty using the pedals (item #19).
Threshold ordering
Other problematic items were identified based on tests assessing threshold ordering. Disordered or narrow thresholds are illustrated via (1) item characteristic curves (Fig. 3) , (2) and logit threshold locations ( Table 2 ). Eleven of 20 CIPN20 items have either disordered responses or small differences between response options: the points between adjacent response curves (Fig. 3) where either response is equally Table 2 in which the threshold logit (point of curve overlap) should progress from lower to higher logit threshold values. For example, the logit thresholds for item CIPN 1 (tingling in fingers and hands) show ordered responses because threshold 1 (−2.5776)-the overlap point between experiencing no neuropathy and a little neuropathy-is lower than threshold 2 logit (−0.8158). Similarly, the threshold 2 logit is lower than logit 3 (0.1073). If an item is functioning as expected, progressively ordered logits will reflect survey respondents' ability to distinguish differences in CIPN symptoms using the 1-4 response options. In contrast, the item-response curves and logit thresholds for item CIPN 12 (difficulty manipulating small objects) are disordered (threshold logit 2 is larger than logit 3). Another obvious example of disordered responses can be seen when examining the item-response curves and threshold logit values for item 20 (erectile dysfunction); the threshold logit 2 is lower than logit 1. If the response items truly reflect ordinal level data, logit 2 should be higher than logit 1, and there should be a greater distance between the various response options. Instead, the logits overlap and are indistinguishable from each other (see supplemental Person Item Map Figure) . Further, small standard deviations (Table 2) suggest that survey respondents were less able to indicate differences in symptom severity.
Differential item functioning (DIF)
For the DIF analysis, item responses were significantly different when comparing responses of males and females (p < 0.0001), and when comparing patients in four distinct chemotherapy groups: those who received (1) oxaliplatin, (2) paclitaxel alone, (3) paclitaxel plus carboplatin, and (4) a variety of different chemotherapy agents (N06CA) (p < 0.0001) (supplemental Tables 1 and 2 ).
Unidimensionality
Consistent with published findings [23, 25] , the cluster analysis findings illustrated in Fig. 4 suggest the lack of a clear factor structure. Items do not cluster together (items with the same color form a cluster) based on sensory (i.e., items 1-6, 9, 10, and 18), motor (i.e., items 7, 8, 11-15, and 19), or autonomic subscales (i.e., items 16, 17, and 20), as previously defined by Postma et al. [19] .
Discussion
This paper presents the results of a Rasch model-based analysis that expands our current knowledge regarding the QLQ-CIPN20's psychometric properties. Use of the Rasch model to test and modify ordinal-level PRO measures such as the QLQ- While multiple papers support the QLQ-CIPN20's reliability, validity, sensitivity, and responsiveness based on CTT methods [20] [21] [22] [23] [24] [25] [26] [27] [28] , to our knowledge, this is the first paper to suggest that the QLQ-CIPN20 items and response options are not ideal, based on Rasch model testing. Although the findings are consistent with other published reports suggesting the QLQ-CIPN20 is a unidimensional scale [23, 25] , disordered/nonordinal or narrow response thresholds affecting 11 of the 20 items suggest several potential problems with the CIPN20 items. Questions assessing autonomic neuropathy and hearing were not aligned with symptom severity. Other problematic items were those assessing patients' difficulty manipulating small objects, walking due to foot drop, and using pedals. Participants had difficulty distinguishing between the four response items, perhaps because they did not understand the intended meaning of the items, which reflects suboptimal content validity. This hypothesis is supported by our previous work testing the content validity of an abbreviated QLQ-CIPN version that excluded the suboptimal autonomic subscale and hearing loss items [26] . We reported that patients did not fully understand the item about foot drop, leading to the recommendation that this item be revised to ask about Btrouble flexing the ankle because of weakness^instead of Bdifficulty walking because your feet dropped downwards.Â nother potential reason for disordered thresholds may be that respondents did not answer the question honestly so as to avoid a negative consequence (i.e., social desirability). In the current Number Q1 Q2 Q3 Q4 Q5 Q6 Q9  Q10  Q18  Q7 Q8 Q11  Q12  Q13  Q14  Q15  Q19 Q16 Q17 research, responses to item 19 about using pedals were disordered, perhaps partly due to social desirability. Again, this idea is supported by our previous research results: interviewees stated that patients were not likely to answer the question about Busing pedals^honestly due to concerns about losing driving privileges. Although we did not evaluate the content validity of the erection item in our prior research, it is likely that some patients would not answer this question honestly either.
Another possible explanation for the disordered or narrow logit thresholds and suboptimal item scaling could be unclear survey instructions and the number of response options. Again, based on our previous research, patients stated that they were sometimes confused about whether to respond based on the severity or on the frequency of the problem [26] . Other respondents indicated that they would have preferred having more response options; a 0-10 response range might facilitate patients' selection of a response that better reflects their symptom experience. In contrast, some narrow logit thresholds could be corrected by dichotomizing the response options, such as for the erection question, because it may be sufficiently informative merely to determine if the patient is experiencing the problem via a yes/no response.
Consistent with published literature, the DIF analyses revealed that item responses varied by gender and chemotherapy type [27] . The DIF findings regarding chemotherapy type validate that CIPN clinical manifestations vary by causative neurotoxic agent, and variation by gender is most likely related to the different types of chemotherapy received by women and men (e.g., women with breast cancer receive paclitaxel ± carboplatin). Thus, differences in responses are expected and may be unrelated to item response bias.
We were unable to find other comparable studies evaluating the QLQ-CIPN20's psychometric properties using Raschmodeling. However, two PRO measures (Rasch-built Overall Disability Scale, CIPN-Rasch-built Overall Disability Scale) and four provider-completed scales (Total Neuropathy Score, Neuropathy Impairment Scale, Medical Research Council Scale, Inflammatory Neuropathy Cause and Treatment Scale) have been tested using Rasch techniques [40] [41] [42] [43] [44] [45] . Van Nes et al. (2011) used Rasch modeling to test a patientreported disability scale, the Rasch-built Overall Disability Scale (R-ODS), when used by individuals with immunemediated peripheral neuropathies [40] . The authors provide evidence supporting that the R-ODS is a valid measure of neuropathy-associated functional deficits because items not meeting Rasch model expectations (e.g., unidimensionality, threshold ordering, DIF) were removed. The same Rasch methods were used by Binda et al. (2013) to retest and refine the R-ODS for use in a different population-those with CIPN [41] . When CIPN-R-ODS scores were compared to the traditional NCI-CTC grading scale scores, a measure commonly used in therapeutic oncology clinical trials, the sensory NCI-CTC was inferior in discriminating between various levels of neuropathy severity. Although these varied measures had been previously tested and shown to possess adequate reliability and validity, Rasch analyses uncovered additional psychometric limitations that CTT-based parametric testing had not previously revealed. This highlights the importance of evaluating ordinal-level neuropathy measures using Rasch-based analytic methods. Thus, we emphasize that our findings should not lead to the conclusion that the QLQ-CIPN20 is an inferior measure, especially when compared to other extensively validated PROs such as the FACT GOG/NTX that have not undergone Rasch-model testing. The Rasch-model-based testing approach used in the current study might reveal similar limitations if used to test other CIPN PRO measures.
A limitation of this work is that we were unable to evaluate DIF due to education, race, or ethnicity because these data are not available. Since the QLQ-CIPN20 continues to be used widely across the United States and Europe, it will be important to assess item bias based on cultural and regional differences in item interpretation. Until such analyses can be performed, CIPN intervention study results obtained in the United States using the QLQ-CIPN20 may not be directly comparable to similar studies conducted in other countries. Further, objective CIPN measures such as physical examination or nerve conduction studies were not obtained to validate the presence of CIPN. However, objective CIPN measures do not typically correlate with subjective symptoms [15] .
In conclusion, Rasch-model-based testing newly revealed psychometric weaknesses of the QLQ-CIPN20 that can be addressed by eliminating or revising problematic items, and by rescaling the 1-4 item response scale. Alternatively, the new gold standard CIPN measurement approach in future intervention trials could involve use of only the best QLQ-CIPN20 items, which would also allow comparisons across previous trials that utilized the QLQ-CIPN20. Compliance with ethical standards
